Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply

Hyeyeon Hong, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):272-273. Published online February 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0123

View: 2011 Download: 79 Web of Science: 1 Crossref: 1

Original Article

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi

Clin Mol Hepatol. 2024;30(1):49-63. Published online November 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0328

View: 3175 Download: 231 Web of Science: 6 Crossref: 7

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 8122 Download: 422 Web of Science: 20 Crossref: 22

Review

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 5869 Download: 261 Web of Science: 31 Crossref: 34

Letter to the Editor

Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei

Clin Mol Hepatol. 2022;28(2):265-266. Published online January 4, 2022

DOI: https://doi.org/10.3350/cmh.2021.0412

View: 7043 Download: 42 Web of Science: 1 Crossref: 1

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 5942 Download: 298 Web of Science: 30 Crossref: 29

Editorial

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 4819 Download: 120 Web of Science: 4 Crossref: 4

Review

Recent advances in nonalcoholic fatty liver disease metabolomics

Hwi Young Kim

Clin Mol Hepatol. 2021;27(4):553-559. Published online June 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0127

View: 11087 Download: 509 Web of Science: 44 Crossref: 47

Original Article

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients

Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim

Clin Mol Hepatol. 2014;20(1):38-46. Published online March 26, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.1.38

View: 9211 Download: 85 Web of Science: 32 Crossref: 31

5

Drug Induced Hepatitis Mimicking Alcoholic Hepatitis

Dae-Young Kang, M.D. and So-Young Jin, M.D.

Clin Mol Hepatol. 2006;12(4):574-578. Published online January 1, 1970

View: 2666 Download: 21

3

Lipid Peroxidation in Chronic Liver Diseases Type B

Kyung Chul Kim , Kwan Sik Lee , Kwang Hyub Han , Won Choi , Chae Yoon Chon , Sang In Lee , Young Myung Moon , Jin Kyung Kang , In Suh Park , Hye Young Kim

Clin Mol Hepatol. 1997;3(1):40-49.

View: 2503 Download: 18

1 |

Viewed By 5058	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 5015	MAFLD: How is it different from NAFLD?
Viewed By 4460	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4420	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4337	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search